HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $47 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on BridgeBio Pharma (NASDAQ:BBIO) with a maintained price target of $47.

March 04, 2024 | 12:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on BridgeBio Pharma with a $47 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating and a maintained price target by a reputable analyst firm like HC Wainwright & Co. typically signals confidence in the company's future performance. This endorsement can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100